IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.365
NA - Nord America 922
AS - Asia 768
SA - Sud America 26
OC - Oceania 12
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.104
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 910
SE - Svezia 606
SG - Singapore 380
RU - Federazione Russa 292
CN - Cina 224
IT - Italia 199
FI - Finlandia 72
GB - Regno Unito 56
DE - Germania 41
IE - Irlanda 33
JP - Giappone 32
IN - India 25
HK - Hong Kong 22
IR - Iran 16
NL - Olanda 14
KR - Corea 13
PT - Portogallo 13
ES - Italia 10
SA - Arabia Saudita 10
TR - Turchia 10
AU - Australia 9
CL - Cile 9
FR - Francia 8
ID - Indonesia 7
MX - Messico 7
EC - Ecuador 6
BR - Brasile 5
GG - Guernsey 5
NO - Norvegia 5
CA - Canada 4
CH - Svizzera 4
EG - Egitto 4
CO - Colombia 3
IQ - Iraq 3
LB - Libano 3
NZ - Nuova Zelanda 3
PL - Polonia 3
TW - Taiwan 3
ZA - Sudafrica 3
CZ - Repubblica Ceca 2
MA - Marocco 2
MM - Myanmar 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
PS - Palestinian Territory 2
SY - Repubblica araba siriana 2
YE - Yemen 2
AE - Emirati Arabi Uniti 1
EE - Estonia 1
EU - Europa 1
MO - Macao, regione amministrativa speciale della Cina 1
MQ - Martinica 1
NG - Nigeria 1
PY - Paraguay 1
RO - Romania 1
TH - Thailandia 1
VN - Vietnam 1
Totale 3.104
Salva come PNG Salva come JPEG
Città #
Lawrence 266
Princeton 266
Singapore 218
Moscow 119
Shanghai 88
Helsinki 66
New York 63
Milan 59
Ashburn 46
Dublin 33
Boardman 26
Los Angeles 26
Hong Kong 21
Leicester 18
Tokyo 18
Guangzhou 16
Rome 12
Daejeon 11
Beijing 10
Buccinasco 9
Fremont 9
Naples 9
Santiago 9
Washington 9
Dallas 8
Kassel 8
Kish 8
Chicago 7
Mumbai 7
Pune 7
Rotherham 7
Shenzhen 7
Azogues 6
Ferrara 6
Jakarta 6
Pisa 6
Borås 5
Boydton 5
Guernsey 5
Jiaxing 5
Lappeenranta 5
Santa Clara 5
Falkirk 4
Hoofddorp 4
Izmir 4
Makkah 4
Perugia 4
Seattle 4
St Petersburg 4
Adana 3
Amsterdam 3
Andover 3
Augsburg 3
Barnet 3
Bologna 3
Brixen 3
Ciudad Nezahualcoyotl 3
Durham 3
Erbil 3
Hamm 3
Hanover 3
Krakow 3
League City 3
North Augusta 3
Paris 3
Pearland 3
Seville 3
Wednesbury 3
Wuxi 3
Ahmedabad 2
Albignasego 2
Albizzate 2
Alexandria 2
Arequipa 2
Auckland 2
Aveiro 2
Barcelona 2
Blackheath 2
Bogotá 2
Boston 2
Brisbane 2
Buffalo 2
Buk-gu 2
Buscate 2
Castelo do Neiva 2
Chennai 2
Dalian 2
Dammam 2
Deiva Marina 2
Delhi 2
Egham 2
Foggia 2
Fort Gibson 2
Foshan 2
Frattaminore 2
Freiburg im Breisgau 2
Gatchina 2
Gaziantep 2
Guadalajara 2
Hackney 2
Totale 1.690
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 228
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 51
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 42
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 38
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 32
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 28
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 27
The impact of histopathologic diagnosis on the proper management of testis neoplasms 26
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 26
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 26
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 25
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 25
Chronic lymphocytic leukemia 23
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 23
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 22
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 21
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 21
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 21
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 20
A multicenter study of treatment of primary CNS lymphoma 20
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 20
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 19
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 19
Primary central nervous system lymphoma 19
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 18
Breaching the blood–brain tumor barrier for tumor therapy 18
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 17
High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial 17
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 17
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-DoseCytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis 17
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients 17
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 17
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 17
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 16
Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma 16
Primary cardiac lymphoma in immunocompetent patients - Diagnostic and therapeutic management 16
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 16
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 16
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 15
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 15
Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring 15
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 15
Microvessel density is an independent predictor of survival in multiple myeloma patients. 15
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 15
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 15
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms 14
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma 14
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 14
Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here? 14
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 14
F-18-FDG pet after allogeneic stem cell transplantation in lymphoid malignancies: A useful tool to guide and monitor post-transplant immunotherapy 14
Chronic lymphocytic leukaemia 14
Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-Cell gastric lymphomas 14
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 13
New hopes in relapsed refractory primary central nervous system lymphoma 13
Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation 13
Allografting for patients with advanced hematological malignancies: Non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with HSV thymidine kinase gene. 13
MATILDE chemotherapy regimen for primary CNS lymphoma Results at a median follow-up of 12 years 13
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21 13
Genomic profiles of MALT lymphomas: variability across anatomical sites 13
Questions and answers in the management of primary central nervous system and ocular lymphomas 13
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 13
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 12
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 12
Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options 12
Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis 12
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome 12
Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas 12
Rituximab improves outcome in Western patients with intravascular large B-cell lymphoma (IVL) 12
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 12
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 12
Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy 12
Le infezioni erpetiche nel paziente immunocompromesso 12
RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE (HD-MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (HD-ARAC) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (IELSG # 20 TRIAL): TOLERABILITY, ACTIVITY AND SURVIVAL ANALYSES 12
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 12
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group 11
Erratum to ‘How we treat primary central nervous system lymphoma’: [ESMO Open Volume 6, Issue 4, August 2021, 100213] (ESMO Open (2021) 6(4), (S2059702921001745), (10.1016/j.esmoop.2021.100213)) 11
Chlamydial infection: the link with ocular adnexal lymphomas 11
Gastric lymphoma: The histology report 11
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 11
Irradiation fields and doses in glioblastoma multiforme: Are current standards adequate? 11
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma 11
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 11
Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation 11
Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL) 11
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 11
Extranodal non-gastric malt lymphomas: An international survey of 278 cases. 11
Therapeutic role of rituximab in the treatment of intravascular lymphoma 11
Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae 11
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 11
Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation 11
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy 11
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies 11
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma 11
Up-front chemotherapy (CHT) containing high-dose methotrexate (HDMTX) followed or not by radiotherapy (RT) in Primary CNS lymphoma (PCNSL): a critical review of prospective trials 11
A retrospective series of upfront therapy in primary brain lymphomas 11
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 11
Primary central nervous system lymphoma in immunocompetent patients 11
Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion 11
Targeted therapies make room, anti-CD79b agents are coming 10
Totale 1.821
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 1 0 1 0 0 0
2020/202134 0 0 0 2 2 3 23 0 3 1 0 0
2021/2022230 0 0 2 71 9 6 15 90 4 5 1 27
2022/20231.328 620 271 55 6 9 135 42 85 53 10 17 25
2023/2024896 39 36 42 58 237 121 57 67 36 52 47 104
2024/2025887 554 60 44 124 105 0 0 0 0 0 0 0
Totale 3.397